Oral Nalbuphine in Idiopathic Pulmonary Fibrosis–Associated Cough

Does nalbuphine extended release (ER) reduce cough and improve patient-reported outcomes in patients with idiopathic pulmonary fibrosis (IPF) and chronic cough?In this randomized, double-blind study of 165 patients with IPF and at least 8 weeks of chronic cough, nalbuphine ER 27 mg, 54 mg, and 108 mg twice daily reduced 24-hour cough count from baseline by 47.9%, 53.4%, and 60.2%, respectively, compared with placebo (16.9%) at 6-week follow-up.For patients with IPF and chronic cough, treatment with nalbuphine ER decreased cough frequency and improved patient-reported outcomes at 6 weeks.

Corresponding Author: Philip L. Molyneaux, MD, PhD, National Heart and Lung Institute, Imperial College London, Victor Phillip Dahdaleh Building, London W12 0NN, United Kingdom (p.molyneaux@imperial.ac.uk).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.